Post-Lehmans: How the structured products market has come of age

STRUCTURED PRODUCTS

clock

Tony King, partner at Mariana Capital, takes a look at how changes in the financial markets over the past five years, have impacted the future of structured products.

A brief review of public offer structured product brochures from pre-Lehman days, provides an insight into how much this market has changed. Then, there was no disclosure of the identity of the counterparty (legal advice said it should not be done); the description of risks was superficial; and included in the product mix were products with high levels of risk built in. Today, those would not be seen in a public offer (triple index reverse convertibles with 60% American barriers, for example). While many practitioners might argue the regulator’s response to the crisis was somewhat hea...

To continue reading this article...

Join Investment Week for free

  • Unlimited access to real-time news, analysis and opinion from the investment industry, including the Sustainable Hub covering fund news from the ESG space
  • Get ahead of regulatory and technological changes affecting fund management
  • Important and breaking news stories selected by the editors delivered straight to your inbox each day
  • Weekly members-only newsletter with exclusive opinion pieces from leading industry experts
  • Be the first to hear about our extensive events schedule and awards programmes

Join now

 

Already an Investment Week
member?

Login

More on Specialist

Deep Dive: Thematics offer diversification but investors must consider bond sensitivity

Deep Dive: Thematics offer diversification but investors must consider bond sensitivity

‘Dedicated specialists’

James Baxter-Derrington
clock 06 April 2023 • 4 min read
European private equity yet to spend €270bn worth of capital

European private equity yet to spend €270bn worth of capital

Deployment of capital expected

Kathleen Gallagher
clock 04 January 2023 • 1 min read
Early-stage biopharma: An opportunity for strategic investment

Early-stage biopharma: An opportunity for strategic investment

Disproportionately smaller investment

Ali H. Munawar
clock 10 August 2022 • 4 min read
Trustpilot